

February 6, 2025

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Update on Voluntary Liquidation of Suburban Diagnostics (India) Private Limited (Wholly Owned Subsidiary)

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”)

Dear Sir/ Madam,

This is in continuation to our earlier intimation i.e. Outcome of Board Meeting dated January 30, 2025, wherein we had informed that the Board of Directors of Suburban Diagnostics (India) Private Limited, Wholly Owned Subsidiary (hereinafter referred to as “Suburban”), have accorded their in-principle approval for voluntary liquidation of Suburban and expeditious consolidation of its business with the Company on a going concern basis, subject to approval of Members of Suburban and compliance of applicable laws.

In this regard, we wish to inform you that the Members of Suburban in their Extra-Ordinary General Meeting held today i.e. February 6, 2025 at 4:00 P.M. (IST) have accorded their approval for voluntary liquidation of Suburban and expeditious consolidation of its business with the Company on a going concern basis subject to compliance of applicable laws

Further, please note that the requisite disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 was already submitted on January 30, 2025 as a part of initial disclosure.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Vinay Gujral
Company Secretary & Compliance Officer